Advertisement
Advertisement

CTSO

CTSO logo

Cytosorbents Corp.

0.61
USD
Sponsored
0.00
-0.08%
May 08, 15:29 UTC -4
Closed
exchange

After-Market

0.60

0.00
-0.66%

Cytosorbents Corp. Profile

About

CytoSorbents Corporation is a therapeutic medical device company. It develops adsorbent polymer technology for applications in the medical field, primarily to provide blood purification for the treatment of acute and chronic health complications associated with blood toxicity. The Company's product include CytoSorb, which filters cytokines and treat potentially fatal cytokine storm and BetaSorb, which remove beta2-microglobulin from the blood of patients suffering from chronic kidney failure. CytoSorbents Corporation is headquartered in Monmouth Junction, New Jersey.

Info & Links

CEO

Phillip P. Chan

Headquarters

305 COLLEGE ROAD EAST
PRINCETON, NJ 08540, UNITED STATES

Industry

Medical Products

Sector

Medical

Website

www.cytosorbents.com

Auditor

WithumSmith+Brown, PC

Share holders

9,395

Employees

129

Cytosorbents Corp. Statistics

Valuation Measures

Market Capitalization2

38M

Enterprise Value

48.41M

Enterprise Value/EBITDA(ttm)

-3.94

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

1.02

Price to Book(mrq)

6.44

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

71.49%

Operating Margin(ttm)

-41.68%

Profit Margin(ttm)

-22.41%

Return on Equity(ttm)

-150.53%

Return on Invested Capital(ttm)

-35.44%

Return on Assets(ttm)

-32.75%

Income Statement

Revenue(ttm)

37.06M

Revenue Per Share(ttm)

0.59

Gross Profit(ttm)

26.49M

EBITDA(ttm)3

-12.30M

Net Income Available to Common(ttm)

-8.20M

Diluted EPS(ttm)

-0.13

Share Statistics

Beta (5Y Monthly)

1.47

52-Week Change

-30.00%

S&P 500 52-Week Change

26.60%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

62.70M

Dividend Yield

0.00%

Float4

58.12M

% Held by Insiders

7.30%

% Held by Institutions

32.87%

Balance Sheet

Total Cash(mrq)

6.25M

Total Cash Per Share(mrq)

0.10

Total Debt(mrq)

16.67M

Total Debt/Equity(mrq)

282.35%

Current Ratio(mrq)

2.13%

Quick Ratio(mrq)

1.58%

Book Value Per Share(mrq)

0.09

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.20

Free Cash Flow(ytd)

-12.46M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement